Novo Nordisk stock falls despite second-quarter earnings and sales beat
GLP-1 sales growth carried the quarter, but shares declined on the report.
TR
By Tom Reyes · Markets Editor
Aug 5 03:00 ETSource: Yahoo Finance
The wire
- 01Novo Nordisk reported second-quarter earnings and sales above expectations, with GLP-1 franchise growth cited as the driver, yet the stock traded lower on the news.
- 02Novo's incretin performance sets the commercial backdrop for semaglutide supply, pricing and competitive pressure from Eli Lilly.
- 03Detail on segment-level figures and guidance was not laid out in the report summary; the share reaction suggests investor focus beyond the headline beat.
From the source
Read at finance.yahoo.comNVO Stock Down Despite Q2 Earnings and Sales Beat on GLP-1 Growth
